Women travel thousands of miles for a reproductive moonshot; scientists say they've been misled

Bulletin.

STAT News reports that a procedure developed to prevent mothers from passing mitochondrial disease to their children is being marketed abroad as a fertility treatment for older women, a use for which the evidence of benefit is thin. The technique, mitochondrial replacement therapy, combines genetic material from an intended mother, a donor, and a father to produce an embryo with DNA from three people. It was designed, and in some jurisdictions approved, specifically to help families avoid transmitting inherited mitochondrial disorders.

According to the investigation, clinics have begun offering the same procedure to women facing age-related infertility, on the premise that donor mitochondria might improve egg quality or embryo viability. Patients described traveling thousands of miles, in some cases to clinics operating outside the regulatory frameworks that govern the therapy’s approved use, to pursue the treatment.

Scientists cited in the report say they were unaware their research was being invoked to support this application, and that current evidence does not establish the procedure’s effectiveness for age-related infertility. The report frames the gap between the therapy’s narrow, evidence-based original purpose and its broader marketing as a matter of informed consent, noting that patients making costly and invasive decisions were doing so without the evidentiary basis they believed they had.

The Specola notes this bulletin summarizes reporting by STAT News, published November 2, 2026.